TARGETING DRUG TO HIV SANCTUARY IN LYMPHATICS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 现有的HAART(高效抗病毒疗法)能有效地将血液中的HIV降至检测不到的水平，停药或携带耐药病毒后病毒反弹导致进展为艾滋病。目前的数据表明，关键组织中的残留病毒，主要是淋巴和脑，导致艾滋病毒疾病的进展。该计划的目标是改善抗HIV药物在淋巴组织和细胞中的定位，以便从这些组织中消除残留病毒。该计划计划开发一种药物输送系统，在大脑和中枢神经系统的其他组织中提供最大限度的药物暴露和病毒抑制。这项技术不是将药物存放在鼻腔细胞中，而是将药物存放在嗅觉细胞中，并提供直接进入大脑和中枢神经系统的途径，从而提高中枢神经系统的传递效率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The existing HAART (highly active antiviral therapy) is effective in reducing HIV in blood to undetectable levels, the virus rebound after cessation of drug or harboring resistance virus leads to progression to AIDS. Current data indicate that residual virus in key tissues, mainly lymphoid and brain, lead to HIV disease progression. The objective of this program has been to improve localization of anti-HIV drugs to lymphoid tissues and cells so that residual virus will be eliminated from these tissues. This program plans to develop a drug delivery system that provides maximum drug exposure and viral suppression in the brain and other tissues of the central nervous system. Instead of depositing drugs in nasal cells, this technology deposits drugs in olfactory cells and provides direct access to the brain and CNS, thereby improving the efficiency of CNS delivery.